Boswellia serrata — Indian Frankincense

Boswellia Serrata
(Frankincense)
Extract

Research-based guidance on Boswellia serrata and standardized frankincense extracts — including composition, studied health benefits, safety considerations, traditional use, and current clinical evidence.

Explore the Research Learn About Boswellia →

Educational only; not medical advice. Summarises research findings and limitations.

Botanical plate illustration of Boswellia serrata (Indian Frankincense), showing the tree, compound leaves, flowers, and resin exudation from the trunk

Boswellia serrata  ·  Burseraceae

Peer-Reviewed Sources Only
Evidence Graded by Strength
Limitations Reported Transparently
Commercial Relationships Clearly Disclosed
Research Areas

Health Areas Examined in Published Studies

The following conditions have been investigated in published clinical trials and laboratory studies involving Boswellia serrata extracts. Evidence strength and study quality vary considerably by condition.

Moderate Evidence (most studied)

Osteoarthritis of the Knee

Multiple randomized controlled trials have evaluated Boswellia serrata extract in individuals with knee osteoarthritis. A 2020 meta-analysis of seven RCTs reported statistically significant differences in pain scores and physical function measures, though effect sizes were modest, clinical significance is uncertain, and most trials were manufacturer-funded. Independent replication is limited.

Review the trials →
Mechanistic Evidence

Inflammatory Pathways (Mechanistic Research)

In laboratory studies (in vitro and animal models), boswellic acids — particularly AKBA — have been shown to inhibit 5-lipoxygenase, an enzyme involved in leukotriene synthesis. This is a mechanistic observation only. Whether this laboratory finding translates to clinically meaningful outcomes in humans at achievable oral doses has not been established.

Read the science →
Mixed / Limited Evidence

Inflammatory Bowel Conditions

Boswellia extracts have been investigated in individuals with ulcerative colitis and Crohn's disease. Results are inconsistent across trials. One controlled trial found non-inferiority to mesalazine in active ulcerative colitis; a larger maintenance trial in Crohn's disease found no significant benefit over placebo. Evidence is considered limited and mixed.

View research →
Moderate Evidence

Bronchial Asthma

Several controlled trials have investigated Boswellia serrata in individuals with chronic bronchial asthma. Some trials reported differences in symptom frequency and spirometry measures between groups, though trials have been small, methodology varies, and clinical significance is uncertain. These findings do not support use as a replacement for prescribed respiratory medications.

View research →
Preliminary Only

Neurological & Cognitive Research

Incensole acetate, a terpenoid compound found in some Boswellia species, has demonstrated anxiolytic and neuroprotective properties in animal models. Human clinical evidence is limited to one small pilot trial. No conclusions about cognitive benefit in humans can be drawn from current data.

View research →
Early Research

Topical & Dermatological Applications

A small number of clinical studies have evaluated topical Boswellia preparations for age-related skin changes. Findings are early-stage and based on limited sample sizes. Frankincense essential oil is used in cosmetic applications, though evidence for specific dermatological benefit in humans remains insufficient.

View research →
Evidence Summary

Research Quality by Health Area

This summary reflects the current state of published clinical evidence. Evidence grades are assigned based on trial design, sample size, replication, and independence from industry funding. Grades may change as new research is published.

Osteoarthritis (Knee)

Moderate–Strong

Multiple RCTs and a 2020 meta-analysis (n=545) report statistically significant differences in pain and function measures. Most trials are small and industry-funded; effect sizes were modest and clinical significance is uncertain. Independent replication is limited.

Bronchial Asthma

Moderate

Several small controlled trials suggest possible symptom reduction. Methodology varies across studies. Evidence does not support use as a substitute for standard asthma treatment.

Ulcerative Colitis

Limited

One trial found non-inferiority to mesalazine in active disease. Findings have not been consistently replicated. Evidence is insufficient to draw clinical conclusions.

Crohn's Disease

Insufficient

A large maintenance trial (Boswelan study) found no statistically significant benefit over placebo for remission maintenance. Current evidence does not support clinical use for this indication.

Brain & Cognition

Preliminary

Animal model data is available for incensole acetate. Human clinical evidence is limited to one small pilot study. No conclusions about cognitive benefit can be drawn from current data.

Oncology (Preclinical)

Insufficient

In vitro studies have examined boswellic acid activity in cancer cell lines. There is no adequate human clinical trial evidence. Boswellia should not be considered a cancer treatment or preventive agent.

Background & Context

About Boswellia serrata

Boswellia serrata is a deciduous tree native to the dry hill forests of India, Pakistan, and Bangladesh. The oleogum resin extracted from incisions in its bark — commonly referred to as frankincense or Indian olibanum — has been used in Ayurvedic medicine for centuries, documented in classical texts including the Sushruta Samhita under the name Shallaki.

Over 20 Boswellia species have been identified. Each species produces a distinct chemical profile; research findings from one species do not necessarily apply to others. The majority of published clinical research has investigated Boswellia serrata specifically.

Read the Historical Record
20+
Boswellia species identified; B. serrata is the most studied in clinical trials
Centuries
of documented traditional use in Ayurveda; precise historical dating is uncertain
30–65%
Boswellic acid content in standardized research extracts; unstandardized products vary widely
AKBA
Most studied boswellic acid; inhibits 5-LOX in vitro; clinical significance still under investigation
Phytochemistry

Active Compounds Under Investigation

Boswellia serrata resin contains a complex mixture of boswellic acids and terpenoids. The following compounds have received the most attention in pharmacological and clinical research. Understanding their properties helps contextualize what the research is — and is not — measuring.

1

AKBA — 3-O-Acetyl-11-Keto-β-Boswellic Acid

The most extensively studied boswellic acid. In vitro studies have demonstrated that AKBA selectively inhibits 5-lipoxygenase (5-LOX), an enzyme involved in leukotriene synthesis. Whether this laboratory mechanism translates to clinically meaningful anti-inflammatory effects in humans at achievable oral doses remains an active area of research.

2

KBA — 11-Keto-β-Boswellic Acid

A related boswellic acid that shares structural features with AKBA. KBA has been shown in laboratory studies to interact with drug transporter proteins OATP1B3 and MRP2 — findings that may be relevant when evaluating potential interactions with medications processed hepatically. Clinical significance of this transporter interaction has not been fully characterized.

3

α- and β-Boswellic Acids

Additional boswellic acid constituents present in whole resin extracts. Some research has investigated whether full-spectrum extracts produce different outcomes compared to isolated compounds, though the clinical data comparing extract types are limited and difficult to interpret due to differences in study design and extract standardization.

4

Incensole Acetate

A terpenoid found primarily in Boswellia sacra resin rather than B. serrata. Animal studies have identified anxiolytic and ion channel effects. One small human pilot study investigated its relevance to mood. Evidence in humans remains insufficient to support clinical conclusions. It is important to note that findings from B. sacra research do not apply to B. serrata supplements.

Evidence Quality Overview

Relative evidence strength by research area, based on trial design and replication in published literature.

AKBA
Osteoarthritis outcomes (RCTs)Moderate (most studied)
Inflammatory pathways (mechanistic)Mechanistic only
IBD trials (UC / Crohn's)Mixed / Limited
Respiratory outcomes (small trials)Limited
Brain & cognition (pilot / animal)Preliminary
Research Library

In-Depth Research Reviews

Each article summarizes selected published peer-reviewed literature, identifies evidence quality, and reports study limitations alongside findings. Content may be updated as new research becomes available.

Joint Health

Boswellia in Osteoarthritis Clinical Trials: What the Studies Show

A structured review of randomized controlled trials evaluating Boswellia serrata in knee osteoarthritis — covering trial design, extract types used, effect sizes, funding sources, and methodological limitations.

8 min read · February 2026
Science

How Boswellic Acids Inhibit 5-Lipoxygenase

5 min read
History

Frankincense: From Ancient Trade Routes to Modern Capsules

6 min read
Dosage

How to Choose a High-Quality Boswellia Supplement

7 min read
Safety

Boswellia Side Effects, Drug Interactions & Who Should Avoid It

6 min read
Extract & Dosage Research

Dosage Ranges Used in Clinical Trials

The following dosage ranges reflect those used in published clinical research. They are not personal dosage recommendations. Extract composition varies significantly between products, and the appropriate dose — if any — depends on extract type, standardization, and individual health circumstances. Consult a qualified healthcare provider before using any supplement.

100–300mg
High-AKBA Extracts

Enriched Formulations

Patented high-AKBA extracts (e.g., Aflapin®, AprèsFlex®) have been studied at 100–250mg/day in small RCTs. These trials reported statistically significant differences in joint pain scores; however, most were conducted or funded by the patent holders, clinical significance is uncertain, and independent replication is limited.

Research range only
300–600mg
Standardized Extracts

Most Frequently Studied Range

Standard extracts standardized to 30–65% boswellic acids have been studied most frequently at 300–600mg/day, administered in divided doses. Multiple RCTs in this range have reported changes in pain and function outcomes over 4–12 weeks. Quality and blinding of trials varies.

Research range only
≤1,000mg
Upper Range Studied

Upper Dosage Range in Trials

The highest doses used in controlled trials reached approximately 1,000mg/day over periods of up to six months. At this level, adverse events including gastrointestinal disturbance have been reported. Long-term safety data beyond six months are limited. Higher doses have not been adequately studied; discuss with a clinician.

Research range only
30–65%
Extract Standardization

Standardization in Published Research

Clinical trial extracts are typically standardized to a declared boswellic acid percentage, with AKBA content reported separately. Commercial products vary widely in actual composition. Some products publish third-party testing and standardization data; many do not. Unstandardized products have unknown potency.

Research range only

Boswellia serrata extracts are regulated as dietary supplements and are not approved by the U.S. Food and Drug Administration for the treatment of any disease.